ArticleJIMD reports2015

Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).

Kazuya Tsuboi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.